Endorphins–Development of the Therapeutic Utility of Enkephalin Analogues

  • Robert C. A. Frederickson
Part of the Topics in the Neurosciences book series (TNSC, volume 2)

Abstract

It is now more than a decade since the endogenous opioid peptides were first discovered. This discovery raised the optimistic hope that the elusive analgesic without abuse potential was finally near at hand. A more pessimistic view, on the other hand, opined that attempts to exploit the new discovery along these lines would merely result in the redesign of morphine. This difference of opinion hasn’t yet been finally resolved, but there can be little argument that this discovery caught the imagination of scientists throughout the world and resulted in extensive research in the opioid area. Ten years of research and development now give us more basis for reasoned evaluation of the status of the various opinions. Numerous endogenous opioid systems and multiple opioid receptors have since been characterized and one major result of this phenomenon has been the establishment of the concept that the presence of receptors for a drug in the brain predicts the existence of endogenous ligands for those receptors. This has stimulated the search for new endogenous ligands as leads for development of new neuropharmaceutical agents.

Keywords

Placebo Schizophrenia Morphine Flare Enzymatic Degradation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson, H.B., Jorgensen, B.C., and Engquist, A. Epidural met-enkephalin (FK33-824). A dose-effect study. Acta Anaesth Scand 26:69–71, 1982.CrossRefGoogle Scholar
  2. 2.
    Berger, P.A., Watson, S.J., Akil, H., and Barchas, J.D. The effects of naloxone in chronic schizophrenia. Am J Psych 138:913–918, 1981.Google Scholar
  3. 3.
    Berger, P.A., Watson, S.J., Akil, H., Elliott, G.R., Rubin, R.T., Pfefferbaum, A., Davis, K.A., Barchas, J.D., and Li, C.H. β-endorphin and schizophrenia. Arch Gen Psych 37:635–640, 1980.Google Scholar
  4. 4.
    Bloomfield, S.S., Barden, T.P., and Mitchell, J. Metkepha-mid and meperidine analgesia after post-episiotomy. Clin Pharmacol Ther 34:240–247, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Brantl, V, Pfeiffer, A., Herz, A., Henschen, A., and Lottspeich, F. Antinociceptive potencies of β-casomorphin analogs as compared to their affinities towards μ and δ opiate receptor sites in brain and periphery. Peptides 3:793–797, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    Calimlim, J.F., Wardell, W.M., Sriwatanakul, K., Lasagna, L., and Cox, C. Analgesic efficacy of parenteral metkeph-amid acetate in treatment of post-operative pain. Lancet 1:1374–1375, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Chaillet, P., Couland, A., Zajac, J.M., Fournie-Zaluski, M.C., Costentin, J., and Roques, B.P. The μ rather than the δ subtype of opioid receptors appears to be involved in enkephalin-induced analgesia. Eur J Pharmacol 101:83–90, 1984.CrossRefGoogle Scholar
  8. 8.
    DeWied, D. Neuropeptides and psychopathology. Endeavor 4:154–159, 1980.CrossRefGoogle Scholar
  9. 9.
    Frederickson, R.C.A. Enkephalin pentapeptides–a review of current evidence for a physiological role in vertebrate neurotransmission. Life Sci 21:23–42, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    Frederickson, R.C.A Endogenous opioids and related derivatives. In M. Kuhar and G. Pasternak, eds. Analgesics: Neurochemical, Behavioral and Clinical Perspectives. New York: Raven Press, 1984. pp. 9–68.Google Scholar
  11. 11.
    Frederickson, R.C.A., Smithwick, E.L., Shuman, R., and Bemis, K.G., Metkephamid, a systemically active analog of methionine-enkephalin with potent opioid δ-receptor activity. Science 211:603–604, 1981.PubMedCrossRefGoogle Scholar
  12. 12.
    Frederickson, R.C.A., Parli, C.J., DeVane, G.W. and Hynes, M.D. Preclinical pharmacology of metkephamid (LY127623), a metenkephalin analogue. In: L.S. Harris, ed. NIDA Research Monograph. Vol. 43. 1982. pp. 150–156.Google Scholar
  13. 13.
    Frederickson, R.C.A., Smithwick, E.L., and Henry, D.P. Opioid peptides as brain neurotransmitters with therapeutic potential: basic and clinical studies. In: C. Ajmone-Marsan and W.Z. Traczyk, eds. Neuropeptides and Neural Transmission. New York: Raven Press, 1980. pp. 227–235.Google Scholar
  14. 14.
    Frenk, H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res Reviews 6:197–210, 1983.CrossRefGoogle Scholar
  15. 15.
    Frenk, H., Urea, G., and Liebeskind, J.C. Epileptic properties of leucine and methionine-enkephalin: comparison with morphine and reversibility by naloxone. Brain Res 147:327–337, 1978.PubMedCrossRefGoogle Scholar
  16. 16.
    Gacel, G., Fournie-Zaluski, M.C., Fellion, E., and Roques, B.P. Evidence of the preferential involvement of μ receptors in analgesia using enkephalins highly selective for peripheral μ or δ receptors. J Med Chem 24:1119–1124, 1981.PubMedCrossRefGoogle Scholar
  17. 17.
    Goodman, R.R., Snyder, S.H., Kuhar, M.J. and Young, W.S. III. Differentiation of delta-opiate and mu-opiate receptor localizations by light microscopic autoradiography. Proc Natl Acad Sci, USA 77:6239–6243, 1980.PubMedCrossRefGoogle Scholar
  18. 18.
    Holaday, J.W., and Faden, A.I. Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature 275:450–451, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Hylden, J.L.K. and Wilcox, G.L. Intharecal opioids block a spinal action of Substance P in mice: functional importance of both μ- and δ- receptors. Eur J Pharmacol 86:95–98, 1983.CrossRefGoogle Scholar
  20. 20.
    Hynes, M.D., and Frederickson, R.C.A. Cross-tolerance studies distinguish morphine- and metkephamid-induced analgesia. Life Sciences 31:1201–1204, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Kline, N.S., Li, C.H., and Lehmann, H.E., β-endorphin-induced changes in schizophrenic and depressed patients. Arch Gen Psych 34:1111–1113, 1977.Google Scholar
  22. 22.
    Kosterlitz, H.W., Lord, J.A.H., Paterson, S.J. and Water-field, A.A. Effects of changes in the structure of enkephalins and of narcotic analgesic drug on their interactions with μ- and δ-receptors. Br J Pharmacol 68:333–342, 1980.PubMedGoogle Scholar
  23. 23.
    Lang, R.E., Bruckner, U.B., Kempf, B., Rascher, W., Sturm, V., Unger, T.H., Speck, G. and Ganten, D. Opioid peptides and blood pressure regulation. Clin and Exper Hyper-Theory and Practice A4 (1–2):249–269, 1982.CrossRefGoogle Scholar
  24. 24.
    Marks, N. Enzymes in the metabolism of opioid peptides: purification, assay and specificity. In NIDA Research Monograph R. S. Rapaka and R. L. Hawks, eds.Google Scholar
  25. 25.
    Marx, J.L. Brain opiates in mental illness. Science 214:1013–1015, 1981.PubMedCrossRefGoogle Scholar
  26. 26.
    McKay, L.D., Kenney, N.J., Edens, N.K., Williams, R.H. and Woods, S.C. Intracerebro-ventricular beta-endorphin increases food intake in rats. Life Sci 29:1429–1434, 1981.PubMedCrossRefGoogle Scholar
  27. 27.
    Meisenberg, G., and Simmons, W.H. Peptides and the Blood-Brain-Barrier. Life Sci 32:2611–2623, 1983.PubMedCrossRefGoogle Scholar
  28. 28.
    Meites, J., Bruni, J.F., Van Vugt, D.A., and Smith, A.F. Relation of endogenous opioid peptides and morphine to neuroendocrine functions. Life Sci 24:1325–1336, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Meyerson, B.J., and Terenius, L. β-endorphin and male sexual behavior. Eur J Pharmacol 42:191, 1977.PubMedCrossRefGoogle Scholar
  30. 30.
    Miglecz, E., Szekely, J.I., and Dumai-Kovacs, Z. Comparison of tolerance development and dependence capacities of morphine, β-endorphin and (D-Met2, and Pro5)-enkephalina-mide. Psychopharmacol 62:29–34, 1979.CrossRefGoogle Scholar
  31. 31.
    Morley, J.S. Structure-activity relationships of enkephalin-like peptides. Ann Rev Pharmacol Toxicol 20:81–110, 1980.CrossRefGoogle Scholar
  32. 32.
    Oyama, T., Jin, T., Yamaya, R., Ling, N. and Giullemin, R. Profound analgesic effects of β-endorphin in man. Lancet 1:122–125, 1980.PubMedCrossRefGoogle Scholar
  33. 33.
    Pardridge, W.M. Neuropeptides and the Blood-Brain-Barrier. Ann Rev Physiol 45:73–82, 1983.CrossRefGoogle Scholar
  34. 34.
    Pert, C.B., Pert, A. Chang, J.K. and Fong, B.T.W. (D-Ala2)-Metenkephalinamide: a potent long-lasting synthetic pentapeptide analgesic. Science 194:330–332, 1976.PubMedCrossRefGoogle Scholar
  35. 35.
    Romer, D., Buscher, H.H., Hill, R.C., Pless, J., Bauer, W., Cardinaux, F., Closse, A., Hauser, D., and Huguenin, R A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature 268:547–549, 1977.CrossRefGoogle Scholar
  36. 36.
    Rogues, B.P. Inhibitors of enkephalin-degrading enzymes as new analgesics: Rational design, biochemical and pharmacological properties. In NIDA Research Monograph. R. S. Rapaka and R. L. Hawks, eds.Google Scholar
  37. 37.
    Roques, B.P., Fournie-Zaluski, M.C., Soroca, E., Lecomte, J.M., Malfroy, B., Llorens, C, and Schwartz, J.C. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature 288:286–288, 1980.PubMedCrossRefGoogle Scholar
  38. 38.
    Shah, N.S., and Donald, A.G. eds. Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications New York: Plenum, 1982.Google Scholar
  39. 39.
    Stacher, G., Bauer, P., Steinringer, H., Schreiber, E., and Schmierer, G. Effects of the synthetic enkephalin analogue FK33-824 on pain threshold and pain tolerance in man. Pain 7:159–172, 1979.PubMedCrossRefGoogle Scholar
  40. 40.
    Stubbs, W.A., Jones, A., Edwards, C.A.W., Delitala, D., Jeffcoate, W.J., and Ratter, S. J. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet 2:1225–1227, 1978.PubMedCrossRefGoogle Scholar
  41. 41.
    Tseng, L.F. Tolerance and cross-tolerance to morphine after chronic spinal DADL infusion. Life Sci 31:987–992, 1982.PubMedCrossRefGoogle Scholar
  42. 42.
    Tung, A.S., and Yaksh, T.L. Ln vivo evidence for multiple opiate receptors mediating analgesia in the rat spinal cord. Brain Res 247:75–83, 1982.PubMedCrossRefGoogle Scholar
  43. 43.
    Verebey K., ed. Opioids in Mental Illness: Theories, Clinical Observations and Treatment Possibilities. New York: The New York Academy of Sciences, 1982.Google Scholar
  44. 44.
    Von Graffenried, B., del Pozo, E., Roubicek, J. Krebs, E., Poldinger, W., Burmeister, P., and Kerp, L. Effects of the synthetic enkephalin analogue FK33-824 in man. Nature 272:729–730, 1978.CrossRefGoogle Scholar
  45. 45.
    Watson, S.J., Akil, H., and Berger, P.A. Some observations on the opiate peptides and schizophrenia. Arch Gen Psych 36:220–223, 1979.Google Scholar
  46. 46.
    Wei, E.T. Enkephalin analogs and physical dependence. J PET 216:12–18, 1981.Google Scholar
  47. 47.
    Wei, E.T., and Loh, H. Physical dependence on opiate-like peptides. Science 193:1262–1263, 1976.PubMedCrossRefGoogle Scholar
  48. 48.
    Yaksh, T.L., Wang, J.T. and Howe, J.R. The pharmacology of spinal pain modulatory systems. In: J. Bonica, ed. Recent Advances in the Management of Pain. NY: Raven Press, 1984.Google Scholar

Copyright information

© Matinus Nijhoff Publishing, Boston 1986

Authors and Affiliations

  • Robert C. A. Frederickson
    • 1
    • 2
  1. 1.The Lilly Research LaboratoriesEli Lilly & CompanyIndianapolisUSA
  2. 2.Central Nervous System Research, Health Care Division–G3WEMonsanto CompanySt LouisUSA

Personalised recommendations